Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

SHE:002294 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	1,125	1,322	2,670	3,236	865.13
Short-Term Investments	988.85	695.51	531.58	-	-
Trading Asset Securities	733.86	186.06	328.36	60	214.59
Cash & Short-Term Investments	2,848	2,204	3,530	3,296	1,080
Cash Growth	29.25%	-37.58%	7.12%	205.25%	-18.20%
Accounts Receivable	565.87	545.38	557.72	474.03	526.57
Other Receivables	23.85	21.01	23.4	155.48	30.63
Receivables	589.72	566.39	581.12	629.51	557.2
Inventory	506.76	490.86	543.53	420.45	391.56
Prepaid Expenses	-	-	-	-	1.13
Other Current Assets	80.02	52.43	56.36	58	102.31
Total Current Assets	4,025	3,313	4,711	4,404	2,132
Property, Plant & Equipment	1,430	1,457	1,506	1,638	1,507
Long-Term Investments	1,840	1,701	963.07	854.48	835.67
Goodwill	10.91	10.91	60.53	87.14	87.14
Other Intangible Assets	1,335	1,318	965.46	1,048	1,244
Long-Term Deferred Tax Assets	151.24	87.4	88.42	82.01	98.26
Long-Term Deferred Charges	1,597	1,416	1,344	1,047	816.84
Other Long-Term Assets	77.26	93.31	116.64	83.09	197.43
Total Assets	10,466	9,397	9,755	9,244	6,918
Accounts Payable	126.09	156.01	219.65	187.67	223.39
Accrued Expenses	717.67	491.34	558.35	487.02	327.04
Short-Term Debt	120	40	177.19	63	300.26
Current Portion of Leases	9.7	10.93	11.46	6.99	-
Current Income Taxes Payable	7.15	10.49	28.92	37.2	10.7
Current Unearned Revenue	38.36	29.55	42.66	97.99	53.23
Other Current Liabilities	94	76.77	565.4	132.98	182.37
Total Current Liabilities	1,113	815.08	1,604	1,013	1,097
Long-Term Debt	-	-	-	-	90
Long-Term Leases	4.18	12.54	19.58	9.11	-
Long-Term Unearned Revenue	142.04	84.11	98.53	93.71	89.61
Long-Term Deferred Tax Liabilities	20.97	13.04	27.18	-	19.82
Other Long-Term Liabilities	433.14	416.47	29.64	82.57	30.41
Total Liabilities	1,713	1,341	1,779	1,198	1,327
Common Stock	1,115	1,115	1,115	1,115	1,046
Additional Paid-In Capital	1,928	1,900	1,866	1,930	-
Retained Earnings	5,620	5,564	5,529	5,330	4,798
Treasury Stock	-	-602.16	-602.16	-327.86	-327.75
Comprehensive Income & Other	49.3	42.22	33.24	-13.41	-7.69
Total Common Equity	8,712	8,019	7,941	8,034	5,508
Minority Interest	40.17	36.43	35.81	11.91	83.33
Shareholders' Equity	8,752	8,055	7,977	8,046	5,592
Total Liabilities & Equity	10,466	9,397	9,755	9,244	6,918
Total Debt	133.88	63.47	208.23	79.1	390.26
Net Cash (Debt)	2,714	2,140	3,322	3,217	689.46
Net Cash Growth	26.83%	-35.58%	3.28%	366.56%	-29.40%
Net Cash Per Share	2.44	1.92	3.02	3.01	0.68
Filing Date Shares Outstanding	1,115	1,091	1,091	1,103	1,029
Total Common Shares Outstanding	1,115	1,091	1,091	1,103	1,029
Working Capital	2,912	2,498	3,108	3,391	1,035
Book Value Per Share	7.81	7.35	7.28	7.29	5.36
Tangible Book Value	7,366	6,690	6,915	6,898	4,177
Tangible Book Value Per Share	6.61	6.13	6.34	6.26	4.06
Buildings	1,222	1,218	1,208	1,218	946.22
Machinery	1,258	1,203	1,138	1,109	923.7
Construction In Progress	62.33	34.35	37.6	94.13	343.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.